Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells

Area of Science:

• Ophthalmology and Molecular Biology
• Investigates cellular mechanisms relevant to age-related macular degeneration (AMD) pathogenesis.

Background:

• Age-related macular degeneration (AMD) is a leading cause of vision loss.
• Anti-VEGF therapies are standard treatments, but their molecular effects require further elucidation.
• Histone deacetylase (HDAC) inhibitors, like Trichostatin A (TSA), are explored for therapeutic potential.

Purpose of the Study:

• To assess the effects of anti-VEGF drugs (aflibercept, ranibizumab, bevacizumab) and TSA on gene transcription in ARPE-19 cells.
• To analyze the impact of these agents on histone deacetylase (HDAC) activity.
• To understand the molecular pathways modulated by these treatments in the context of AMD.

Main Methods:

• Cultured ARPE-19 cells were treated with varying concentrations of anti-VEGF drugs and TSA.
• Gene transcription profiles were analyzed for genes associated with AMD pathogenesis.
• HDAC activity was measured using a fluorometric assay.

Main Results:

• TSA modulated genes involved in apoptosis (BCL2L13, CASPASE-9) and inflammation (IL-1β, IL-18), and downregulated HIF-1α.
• TSA, alone or combined with bevacizumab, significantly reduced HDAC activity.
• Bevacizumab alone increased expression of genes related to oxidative stress (SOD2) and apoptosis (BCL2L13, CASPASE-3), and downregulated HIF-1α.

Conclusions:

• Anti-VEGF drugs can alter the expression of genes critical for oxidative stress, inflammation, and apoptosis.
• TSA-induced deacetylation impacts transcription of genes involved in angiogenesis, apoptosis, and inflammation.
• Combination therapy with bevacizumab and TSA demonstrates synergistic effects on gene expression and HDAC activity.